drugset
drugset / Trial / NCT04768608

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

NCT04768608 ↗

Phase 1 Completed 3 enrolled Zhejiang University Bioray Laboratories · collab
NaSequentialOpen-labelTreatment

Summary

PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Timeline

Start
2021-12-23
Primary completion
2022-06-30
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject PD1-PSMA-CART cells Cell therapy 0.5 cells/kg Intravenous
Subject PD1-PSMA-CART cells Cell therapy 1 cells/kg Intravenous
Subject PD1-PSMA-CART cells Cell therapy 2 cells/kg Intravenous

Indications

castration-resistant prostate carcinoma